Generation Bio (GBIO) Stock Overview
A biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GBIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Generation Bio Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.56 |
| 52 Week High | US$12.40 |
| 52 Week Low | US$3.00 |
| Beta | 1.96 |
| 1 Month Change | 7.34% |
| 3 Month Change | -2.80% |
| 1 Year Change | -48.04% |
| 3 Year Change | -84.81% |
| 5 Year Change | -98.20% |
| Change since IPO | -97.75% |
Recent News & Updates
Recent updates
Companies Like Generation Bio (NASDAQ:GBIO) Could Be Quite Risky
Nov 14
There Is A Reason Generation Bio Co.'s (NASDAQ:GBIO) Price Is Undemanding
Jul 14Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29%
Mar 16We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Shareholder Returns
| GBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 3.3% | 3.1% |
| 1Y | -48.0% | 26.7% | 14.6% |
Return vs Industry: GBIO underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: GBIO underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| GBIO volatility | |
|---|---|
| GBIO Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GBIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GBIO's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 115 | Yalonda Howze | generationbio.com |
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. Fundamentals Summary
| GBIO fundamental statistics | |
|---|---|
| Market cap | US$37.46m |
| Earnings (TTM) | -US$62.63m |
| Revenue (TTM) | US$15.27m |
Is GBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBIO income statement (TTM) | |
|---|---|
| Revenue | US$15.27m |
| Cost of Revenue | US$47.67m |
| Gross Profit | -US$32.40m |
| Other Expenses | US$30.23m |
| Earnings | -US$62.63m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.29 |
| Gross Margin | -212.17% |
| Net Profit Margin | -410.13% |
| Debt/Equity Ratio | 0% |
How did GBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 14:43 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Generation Bio Co. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Farzin Haque | Jefferies LLC |